Table 2 Patient characteristics
Age, median (range) |  | 59 (18–81) |
|---|---|---|
Gender, N (%) | F | 34 (45) |
| Â | M | 42 (55) |
Stage, N (%) | I | 7 (9) |
| Â | II | 24 (31) |
| Â | III | 22 (30) |
| Â | IV | 23 (30) |
IPI, N (%) | 0–1 | 35 (46) |
| Â | 2 | 19 (25) |
| Â | 3 | 11 (14) |
|  | 4–5 | 11 (14) |
Treatment | R-CHOP-14 | 76 |
Treatment response according to international criteria [26], N (%) | CR | 63 (83) |
| Â | PR | 12 (16) |
| Â | SD | 1 (1) |
| Â | PD | 0 (0) |
Survival, median (IQR) | PFS | 55.05(56.7) |
| Â | EFS | 55.05 (56.7) |
| Â | OS | 61.9 (9.65) |
Cell-of-origin (Tally) [11], N (%) | non-GCB | 44 (58) |
| Â | GCB | 32 (42) |
Double-hit score, N (%) | 0 | 35 (46) |
| Â | 1 | 31 (41) |
| Â | 2 | 10 (13) |
Translocations N (%) | MYC | 5 (9) |
| Â | BCL2 | 6 (11) |